Robert W. Baird Has Lowered Expectations for Revvity (NYSE:RVTY) Stock Price

Revvity (NYSE:RVTY - Get Free Report) had its price target lowered by stock analysts at Robert W. Baird from $141.00 to $127.00 in a report issued on Monday,Benzinga reports. The firm currently has an "outperform" rating on the stock. Robert W. Baird's target price points to a potential upside of 34.68% from the stock's current price.

A number of other equities analysts have also recently commented on RVTY. Wells Fargo & Company dropped their price objective on shares of Revvity from $130.00 to $102.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Sanford C. Bernstein downgraded Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 price objective on the stock. in a research report on Friday, January 10th. Raymond James reaffirmed an "outperform" rating and set a $145.00 target price (up from $140.00) on shares of Revvity in a research report on Monday, February 3rd. KeyCorp raised their price target on Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Finally, Barclays reduced their price objective on shares of Revvity from $140.00 to $110.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Revvity has an average rating of "Moderate Buy" and a consensus target price of $130.50.

Revvity Price Performance

Shares of NYSE:RVTY traded down $0.83 during midday trading on Monday, reaching $94.30. 1,390,004 shares of the company were exchanged, compared to its average volume of 913,815. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41. The stock has a market cap of $11.33 billion, a PE ratio of 42.67, a price-to-earnings-growth ratio of 3.82 and a beta of 1.07. The business's fifty day moving average is $104.87 and its two-hundred day moving average is $113.09. Revvity has a one year low of $88.53 and a one year high of $129.50.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings data on Friday, January 31st. The company reported $1.42 earnings per share for the quarter, beating analysts' consensus estimates of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same quarter last year, the business earned $1.25 earnings per share. As a group, analysts predict that Revvity will post 4.94 earnings per share for the current year.

Insider Buying and Selling at Revvity

In other news, insider Joel S. Goldberg sold 15,170 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the sale, the insider now owns 33,400 shares of the company's stock, valued at $4,232,782. This trade represents a 31.23 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.68% of the company's stock.

Institutional Trading of Revvity

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tidal Investments LLC raised its position in Revvity by 2,388.8% during the third quarter. Tidal Investments LLC now owns 52,787 shares of the company's stock worth $6,744,000 after acquiring an additional 50,666 shares during the period. Principal Financial Group Inc. boosted its holdings in Revvity by 3.1% in the 3rd quarter. Principal Financial Group Inc. now owns 141,871 shares of the company's stock valued at $18,124,000 after purchasing an additional 4,263 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Revvity by 13.7% in the third quarter. JPMorgan Chase & Co. now owns 344,115 shares of the company's stock valued at $43,961,000 after acquiring an additional 41,497 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Revvity by 10.8% in the 4th quarter. GAMMA Investing LLC now owns 1,898 shares of the company's stock valued at $212,000 after purchasing an additional 185 shares during the last quarter. Finally, Nordea Investment Management AB lifted its position in Revvity by 8.0% in the fourth quarter. Nordea Investment Management AB now owns 9,681 shares of the company's stock valued at $1,084,000 after buying an additional 719 shares during the last quarter. Institutional investors and hedge funds own 86.65% of the company's stock.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.